Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.

Rudick RA, Kappos L, Kinkel R, Clanet M, Phillips JT, Herndon RM, Sandrock AW, Munschauer FE 3rd.

Mult Scler. 2011 Mar;17(3):353-60. doi: 10.1177/1352458510384605. Epub 2010 Oct 21.

PMID:
20965959
2.

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.

Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, Goelz SE.

Ann Neurol. 2010 Sep;68(3):304-10. doi: 10.1002/ana.22107.

PMID:
20737514
3.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
4.

Asymptomatic reactivation of JC virus in patients treated with natalizumab.

Gorelik L, Goelz S, Sandrock AW.

N Engl J Med. 2009 Dec 17;361(25):2487-8; author reply 2489-90. doi: 10.1056/NEJMc0909622. No abstract available.

PMID:
20018972
5.

Natalizumab and central nervous system lymphoma: no clear association.

Bozic C, LaGuette J, Panzara MA, Sandrock AW.

Ann Neurol. 2009 Sep;66(3):261-2. doi: 10.1002/ana.21835. No abstract available.

PMID:
19798645
6.

Assessing disability progression with the Multiple Sclerosis Functional Composite.

Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.

Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.

PMID:
19667023
7.

Proof of concept studies for tissue-protective agents in multiple sclerosis.

Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O'Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandrock AW, Waubant E.

Mult Scler. 2009 May;15(5):542-6. doi: 10.1177/1352458508101939. Review.

PMID:
19389749
8.

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.

Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW; GLANCE Investigators.

Neurology. 2009 Mar 3;72(9):806-12. doi: 10.1212/01.wnl.0000343880.13764.69.

9.

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators.

Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Erratum in: Lancet. 2009 Apr 18;373(9672):1340.

PMID:
18970976
10.

LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.

Rudick RA, Mi S, Sandrock AW Jr.

Expert Opin Biol Ther. 2008 Oct;8(10):1561-70. doi: 10.1517/14712598.8.10.1561 . Review.

PMID:
18774923
11.

More on melanoma with transdifferentiation.

Panzara MA, Bozic C, Sandrock AW.

N Engl J Med. 2008 Jul 3;359(1):99; author reply 99-100. doi: 10.1056/NEJMc086089. No abstract available.

PMID:
18596284
12.

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

Neurology. 2007 Apr 24;68(17):1390-401.

PMID:
17452584
13.

Infusion-related hypersensitivity reactions during natalizumab treatment.

Phillips JT, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Polman CH, Lublin FD, Giovannoni G, Wajgt A, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

Neurology. 2006 Nov 14;67(9):1717-8. No abstract available. Erratum in: Neurology. 2007 Feb 6;68(6):473.

PMID:
17101921
14.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

N Engl J Med. 2006 Mar 2;354(9):911-23.

15.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

N Engl J Med. 2006 Mar 2;354(9):899-910.

16.

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.

Rudick RA, Cutter GR, Baier M, Weinstock-Guttman B, Mass MK, Fisher E, Miller DM, Sandrock AW.

Mult Scler. 2005 Dec;11(6):626-34.

PMID:
16323317
17.

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.

Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE, Stuart WH, Ying GS, Galetta SL, Maguire MG, Cutter GR.

Neurology. 2003 Nov 25;61(10):1367-73.

PMID:
14638957
18.

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.

Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators.

Neurology. 2002 Nov 26;59(10):1507-17.

PMID:
12451189
19.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators.

Neurology. 2002 Sep 10;59(5):679-87.

PMID:
12221157
20.

Noninvasive detection of fibrillation potentials in skeletal muscle.

Keller SP, Sandrock AW, Gozani SN.

IEEE Trans Biomed Eng. 2002 Aug;49(8):788-95.

PMID:
12148817
21.

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW.

Ann Neurol. 2002 Apr;51(4):481-90.

PMID:
11921054
22.

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN.

Arch Neurol. 2001 Jun;58(6):961-7.

PMID:
11405811
23.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW.

N Engl J Med. 2000 Sep 28;343(13):898-904.

24.

Heterogeneity of subcellular localization and electrophoretic mobility of survival motor neuron (SMN) protein in mammalian neural cells and tissues.

Francis JW, Sandrock AW, Bhide PG, Vonsattel JP, Brown RH Jr.

Proc Natl Acad Sci U S A. 1998 May 26;95(11):6492-7.

25.

Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo.

Sandrock AW Jr, Dryer SE, Rosen KM, Gozani SN, Kramer R, Theill LE, Fischbach GD.

Science. 1997 Apr 25;276(5312):599-603.

26.

The role of neuregulin (ARIA) at the neuromuscular junction.

Rosen KM, Sandrock AW Jr, Goodearl AD, Loeb JA, Fischbach GD.

Cold Spring Harb Symp Quant Biol. 1996;61:427-34. Review. No abstract available.

PMID:
9246471
27.

ARIA is concentrated in nerve terminals at neuromuscular junctions and at other synapses.

Sandrock AW Jr, Goodearl AD, Yin QW, Chang D, Fischbach GD.

J Neurosci. 1995 Sep;15(9):6124-36.

28.

ARIA is concentrated in the synaptic basal lamina of the developing chick neuromuscular junction.

Goodearl AD, Yee AG, Sandrock AW Jr, Corfas G, Fischbach GD.

J Cell Biol. 1995 Sep;130(6):1423-34.

30.

Primary T-cell lymphoma of the brainstem.

McCue MP, Sandrock AW, Lee JM, Harris NL, Hedley-Whyte ET.

Neurology. 1993 Feb;43(2):377-81. Review.

PMID:
8437706
31.

Analysis of complex matrices functional in neuronal process extension using monoclonal antibodies in vitro and in vivo.

Tuttle R, Sandrock AW, Matthew WD.

Dev Neurosci. 1989;11(4-5):289-99. Review. No abstract available.

PMID:
2676456
32.

Substrate-bound nerve growth factor promotes neurite growth in peripheral nerve.

Sandrock AW Jr, Matthew WD.

Brain Res. 1987 Nov 10;425(2):360-3.

PMID:
3427437
33.
34.

An in vitro neurite-promoting antigen functions in axonal regeneration in vivo.

Sandrock AW Jr, Matthew WD.

Science. 1987 Sep 25;237(4822):1605-8.

PMID:
3306923
35.

Cyclophosphamide treatment used to manipulate the immune response for the production of monoclonal antibodies.

Matthew WD, Sandrock AW Jr.

J Immunol Methods. 1987 Jun 26;100(1-2):73-82.

PMID:
3598198
36.

Vasoactive intestinal peptide: vasodilatation and cyclic AMP generation.

Ganz P, Sandrock AW, Landis SC, Leopold J, Gimbrone MA Jr, Alexander RW.

Am J Physiol. 1986 May;250(5 Pt 2):H755-60.

PMID:
3010741
37.

Regulation of rat pineal hydroxyindole-O-methyltransferase: evidence of S-adenosylmethionine-mediated glucocorticoid control.

Sandrock AW Jr, Leblanc GG, Wong DL, Ciaranello RD.

J Neurochem. 1980 Sep;35(3):536-43.

PMID:
7452273

Supplemental Content

Loading ...
Support Center